Participants in this study must be people who were assigned male sex at birth, people who are living with HIV and are interested in starting feminizing hormones. The goal of this study is to see how certain HIV medications interact with estradiol (one of the hormones prescribed for gender-affirming care).
Participants must meet these requirements (among others):
- 18 Years or older.
- Assigned male sex at birth.
- Living with HIV and taking anti-retroviral therapy for at least 25 weeks (6 months).
- Desire to start or restart feminizing hormone therapy as part of the gender affirming care.
Study Procedures include:
- Daily dosing of estradiol (the feminizing hormone).
- Routine study visits up to 48 weeks after enrolled.
- Blood tests and questionnaires are to be completed during study visits.
- Brief Video Chat interviews.